From: "Kareem Dupree" <kdkkyfibsmsc@poczta.onet.pl>
To: <paliourg@iit.demokritos.gr>
Subject: bongo,Smallcap St0ck of Interest
Date: Wed, 8 Sep 2004 02:31:18 +0300
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-7"
Content-Transfer-Encoding: quoted-printable
X-Priority: 3
X-MSMail-Priority: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2527

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
Iris Lara,<p>


 Genex Pharmaceutical, Inc. (OTCBB: GENX)<P>

Chinese Biotech Company Producing Reconstituted Bone Xenograft (RBX)
Signs Letter  of  Intent  to  Acquire  Vitamin  B1 Manufacturer that
Posted US $16 MILLI0N in Revenue for Fiscal 2003 and Net  Income  of
Approximately US $3 MILLI0N<P>

The 10Q which  was  released  on  August  16th  showed  revenues  of
$525,750  for the quarter ending June 30th. vs. $98,763 for the same
period a year ago.  Net  Income  three  months  ended June 30, 2004:
$151,904 vs. a loss of $3,929 for the same period a year ago.<P><P>


                  About Genex Pharmaceutical, Inc.<P>

        Product Distributed to 400 Hospitals in 22 Provinces<P>

Genex Pharmaceutical, Inc. is a biomedical technology  company  with
distinctive  proprietary  technology  for  an orthopedic device that
treats bone-related injuries.  Headquartered  in Tianjin, China, the
Company manufactures and distributes  Reconstituted  Bone  Xenograft
(RBX),  to  400 hospitals in 22 provinces throughout mainland China.
RBX is approved by the State  Food and Drug Administration (SFDA) in
China (the  Chinese  government  agency  that  regulates  drugs  and
medical  devices).  RBX  offers  a modern alternative to traditional
methods of  treating  orthopedic  injuries.  (Source:   News Release
7/27/04)<P><P>


                  Recent Press Release Headlines:<P>

The Good News Keeps on  Coming  for GENX - Go Read the Full Stories!<P>

*Genex    Pharmaceutical    Adopts   New   Proprietary   Technology,
Substantially Reduces Manufacturing  Costs,  Sees Positive Impact to
Earnings.<P>

*Genex Pharmaceutical Signs Letter of Intent to Acquire One  of  the
World's Largest Producers of Vitamin B1.<P>

*Genex Pharmaceutical Sees Strong Earnings Growth for 2004 and 2005.<P>

*Genex  Pharmaceutical  2nd Quarter Revenue Up 432%, Gross PR0FIT Up
380%,  Net  INC0ME  Soars,  Sees  Continued  Earnings  Momentum  for
Remainder of 2004.<P><P>


                  Strongly Consider The Following:<P>

Many investors (some of them  are  now called millionaires), see the
potential for  emerging  companies  before  the  numbers  grab  Wall
Street's  Attention.   That  's how the big money is made! Were they
just lucky? I don't  think  so-  and  as  an investor, I suspect you
don't either. The truth is, they see something the average  investor
doesn't-   Hidden   Profit  Potential-  make  that  Enormous  Profit
Potential And the rest is history- Very Rich History.<P>

Read the announcements GENX has made.  Look at the Company. Read the
Filings. Do you see  the  Potential  for  Explosive Growth?  You may
agree that's where the big  money  is  made  -  Finding  small  gems
already  top  line producing and poised for massive growth. Consider
GENX for your portfolio today. Good Luck and Successful=20
Investing.<P><P>


DIS-CLAIMER: Information within this ema-il contains F0RWARD looking
statements within the meaning of Section 27A of the  Securities  Act
of  1933 and Section 21B of the Securities Exchange Act of 1934. Any
statements that  express  or  involve  discussions  with  respect to
predictions, expectations, beliefs, plans, projections,  objectives,
goals,   assumptions   or  future  events  or  performance  are  not
statements of historical fact and may be forward looking statements.
Forward looking statements are  based on expectations, estimates and
projections at the time the  statements  are  made  that  involve  a
number  of  risks and uncertainties which could cause actual results
or events to  differ  materially  from  those presently anticipated.
Forward looking statements in this action may be identified  through
the  use  of  words  such  as  projects  ,  foresee,  expects, will,
anticipates, estimates, believes, understands  or that by statements
indicating certain actions may, could, or might occur. As with  many
micro-cap  stocks, today's company has additional risk factors worth
noting. Those  factors  include:  a  limited  operating history: the
company advancing cash to related parties and a  shareholder  on  an
unsecured  basis:  one  vendor,  a  related party through a majority
stockholder, supplies  ninety-seven  percent  of  the  company's raw
materials: reliance on two customers for over fifty percent of their
business and numerous related party transactions  and  the  need  to
raise  capital.These  risk  factors and others are fully detailed in
the company's SEC filings and company press releases. We urge you to
read them before you invest.  The  Publisher of this letter does not
represent that the information contained in this message states  all
material  facts  or  does not omit a material fact necessary to make
the  statements  therein  not  misleading.All  information  provided
within this ema-il  pertaining  to  investing,  ST0CKS or securities
must be  understood  as  information  provided  and  not  investment
advice.  The  Publisher  of  this  letter  advises  all  readers and
subscribers to seek advice from a registered professional securities
representative before deciding  to  trade  in stocks featured within
this ema-il. None of  the  material  within  this  report  shall  be
construed  as any kind of investment advice or solicitation. Many of
these companies are on  the  verge  of  bankruptcy. You can lose all
your money by investing in this stock. The Publisher of this  letter
is  not a registered investment ADVIS0R. Subscribers should not view
information herein as legal,  tax,  accounting or investment advice.
Any reference to past  performance(s)  of  companies  are  specially
selected  to  be  referenced  based  on the favorable performance of
these companies.  You  would  need  perfect  timing  to  acheive the
results in the examples given. There can be  no  assurance  of  that
happening.Remember, as always, past performance is ne-ver indicative
of  future  results and a thorough due diligence effort, including a
review  of  a  company's  filings,  should  be  completed  prior  to
investing.  In  compliance   with   the   Securities  Act  of  1933,
Section17(b),The Publisher of this letter discloses the  receipt  of
thirty  three  thousand  dollars from a third party, not an officer,
director  or  affiliate  shareholder  for  the  circulation  of this
report. Be aware of an inherent conflict of interest resulting  from
such compensation due to the fact that this is a paid adver-tisement
and  is not without bias. All factual information in this report was
gathered from public sources,  including  but not limited to Company
Websites, SEC Filings and Company Press Releases. The  Publisher  of
this letter believes this information to be reliable but can make no
guar-antee  as  to its accuracy or completeness. Use of the material
within this ema-il constitutes your acceptance of these terms.<p>


armata narragansett alphabet colombia burgess contort maloney mellow =
mythic eclogue cupful derrick embarcadero loaf baby ,steprelation andre =
haifa prolific downturn hadrian lawgiving hying cinnamon soap gallivant =
clarke brownian crony baroness hoffman antic droll crump multiplicity =
recurring newport parish gastrointestinal proserpine thruway mosaic yet =
corral autobiography tetrafluoride treachery .prognosticate tortuous =
bonanza octagonal xi podium desuetude minim vera beryl exchange =
coriander instalment munition air jacket ,sensual stearate cloister =
zellerbach asbestos angus break replicate sliver stiff incommensurate =
pursuit beograd markov posy constitute bruce lutz efficacy incomputable =
rosebud lineage sikorsky hydrant irony recess oilcloth adolph =
multipliable combination tippy allspice egret confiscable moral battelle =
cage bali pocketbook .<p>
